Oncology – II Oncology – II These questions cover various advanced aspects of oncology, including molecular biology, genetics, targeted therapies, and cancer metabolism. 1 / 10 Which of the following biomarkers is often elevated in patients with pancreatic adenocarcinoma? Prostate-specific antigen (PSA) CA-125 CA 19-9 Alpha-fetoprotein (AFP) 2 / 10 Which of the following viruses is associated with the development of Kaposi’s sarcoma? Human papillomavirus (HPV) Epstein-Barr virus (EBV) Hepatitis B virus (HBV) Human herpesvirus 8 (HHV-8) 3 / 10 Which of the following drugs is a tyrosine kinase inhibitor that specifically targets the BCR-ABL fusion protein in chronic myeloid leukemia (CML)? Rituximab Imatinib Pembrolizumab Trastuzumab 4 / 10 Which of the following is a known oncogene that is commonly activated by translocations in non-Hodgkin lymphoma? BCL2 TP53 APC BRCA1 5 / 10 Which of the following is a characteristic feature of Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome? Germline mutations in the RB1 gene Germline mutations in the TP53 gene Microsatellite instability Overexpression of HER2 6 / 10 What is the mechanism of action of the drug olaparib, which is used in the treatment of BRCA-mutated ovarian cancer? Inhibition of topoisomerase II Inhibition of poly (ADP-ribose) polymerase (PARP) Blockage of tyrosine kinase receptors Disruption of microtubule assembly 7 / 10 Which of the following genetic alterations is most commonly associated with the development of glioblastoma multiforme? EGFR amplification KRAS mutation ALK rearrangement HER2 amplification 8 / 10 Which of the following is a common side effect associated with the use of immune checkpoint inhibitors in cancer therapy? Hypertension Hyperglycemia Immune-related adverse events (irAEs) such as colitis and pneumonitis Myelosuppression 9 / 10 Which cancer is characterized by a t(14;18) translocation resulting in overexpression of the BCL2 gene? Mantle cell lymphoma Acute myeloid leukemia (AML) Follicular lymphoma Chronic lymphocytic leukemia (CLL) 10 / 10 Which of the following best describes the mechanism of action of the drug bevacizumab? It is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It is a tyrosine kinase inhibitor that targets BCR-ABL. It is an immune checkpoint inhibitor that blocks PD-1. It is an alkylating agent that crosslinks DNA. Your score isThe average score is 0% 0% Restart quiz
